Gastrointestinal

Polpharma looks to challenge Takeda’s Entyvio in IBD

Netherland-based Polpharma Biologics has released topline results from a pharmacokinetic (PK) and pharmacodynamic (PD) study of its biosimilar candidate PB016,…

Inventiva halt recruitment for Phase III NASH trial following adverse event

French biopharmaceutical company, Inventiva has paused recruitment for its pivotal Phase III trial for lanifibranor after a trial participant reported…

Insilico’s AI-discovered ulcerative colitis drug starts Phase I trial

Hong Kong-based Insilico Medicine has launched a Phase I trial of its artificial intelligence (AI)-discovered drug ISM5411. The Phase I…

Pipeline Moves: Approval prospects drop for Bayer’s cardiovascular drug after Phase III termination

This week on Pipeline Moves, we kick off by looking at Phase III trial terminations by Bayer and Johnson &…

Sosei to regain rights to IBD drug after GSK discontinues programme

Sosei Group Corporation has initiated discussions to regain full ownership of the oral inflammatory bowel disease (IBD) drug GSK4381406 from…

InDex Pharmaceuticals terminates Phase III cobitolimod trial

InDex Pharmaceuticals has announced the termination of a Phase III trial of its candidate cobitolimod in patients with ulcerative colitis…

Chimeric to begin gastrointestinal cancer therapy trial

Chimeric Therapeutics has announced plans to commence a Phase IA/B clinical trial of CHM 2101 to treat gastrointestinal cancers. The…

Biora submits updated IND application for ulcerative colitis drug/device trial

Biora Therapeutics has submitted an updated investigational new drug (IND) application with the US Food and Drug Administration (FDA) for…

Phanes and Merck to study PT886 in combination with KEYTRUDA

US-based biopharmaceutical company Phanes Therapeutics has signed a clinical collaboration agreement with Merck, known as MSD outside North America, to…

Lilly’s Crohn’s disease therapy trial meets endpoints

Eli Lilly and Company (Lilly) has reported that the Phase III VIVID-1 study of mirikizumab for the treatment of Crohn's…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close